Literature DB >> 24890451

Cancer treatment and survivorship statistics, 2014.

Carol E DeSantis1, Chun Chieh Lin, Angela B Mariotto, Rebecca L Siegel, Kevin D Stein, Joan L Kramer, Rick Alteri, Anthony S Robbins, Ahmedin Jemal.   

Abstract

The number of cancer survivors continues to increase due to the aging and growth of the population and improvements in early detection and treatment. In order for the public health community to better serve these survivors, the American Cancer Society and the National Cancer Institute collaborated to estimate the number of current and future cancer survivors using data from the Surveillance, Epidemiology, and End Results (SEER) program registries. In addition, current treatment patterns for the most common cancer types are described based on information in the National Cancer Data Base and the SEER and SEER-Medicare linked databases; treatment-related side effects are also briefly described. Nearly 14.5 million Americans with a history of cancer were alive on January 1, 2014; by January 1, 2024, that number will increase to nearly 19 million. The 3 most common prevalent cancers among males are prostate cancer (43%), colorectal cancer (9%), and melanoma (8%), and those among females are cancers of the breast (41%), uterine corpus (8%), and colon and rectum (8%). The age distribution of survivors varies substantially by cancer type. For example, the majority of prostate cancer survivors (62%) are aged 70 years or older, whereas less than one-third (32%) of melanoma survivors are in this older age group. It is important for clinicians to understand the unique medical and psychosocial needs of cancer survivors and to proactively assess and manage these issues. There are a growing number of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship.
© 2014 American Cancer Society.

Entities:  

Keywords:  cancer; prevalence; statistics; survivorship; treatment patterns

Mesh:

Year:  2014        PMID: 24890451     DOI: 10.3322/caac.21235

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  1170 in total

1.  A PET/MR Imaging Approach for the Integrated Assessment of Chemotherapy-induced Brain, Heart, and Bone Injuries in Pediatric Cancer Survivors: A Pilot Study.

Authors:  Ashok J Theruvath; Anat Ilivitzki; Anne Muehe; Johanna Theruvath; Praveen Gulaka; Christine Kim; Sandra Luna-Fineman; Kathleen M Sakamoto; Kristen W Yeom; Phillip Yang; Michael Moseley; Frandics Chan; Heike E Daldrup-Link
Journal:  Radiology       Date:  2017-08-04       Impact factor: 11.105

2.  MicroRNAs used as novel biomarkers for detecting cancer metastasis.

Authors:  Chunshan Han; Haixiang Yu; Lening Zhang; Xiaoli Li; Yonggang Feng; Hua Xin
Journal:  Tumour Biol       Date:  2014-10-31

3.  Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

Authors:  Samantha Russell; Mark Duquette; Joyce Liu; Ronny Drapkin; Jack Lawler; Jim Petrik
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

4.  Spatial Analysis of Growing Follicles in the Human Ovary to Inform Tissue Engineering Strategies.

Authors:  Natalie Quan; Jamie N Mara; Allison R Grover; Mary Ellen Pavone; Francesca E Duncan
Journal:  Tissue Eng Part A       Date:  2020-06-26       Impact factor: 3.845

Review 5.  Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions.

Authors:  Graham W Warren; Kenneth D Ward
Journal:  Transl Lung Cancer Res       Date:  2015-08

6.  N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.

Authors:  Matthew J Scheffel; Gina Scurti; Megan M Wyatt; Elizabeth Garrett-Mayer; Chrystal M Paulos; Michael I Nishimura; Christina Voelkel-Johnson
Journal:  Cancer Immunol Immunother       Date:  2018-02-02       Impact factor: 6.968

7.  Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis.

Authors:  Shannon D Armbruster; Jaejoon Song; Leticia Gatus; Karen H Lu; Karen M Basen-Engquist
Journal:  Gynecol Oncol       Date:  2018-02-01       Impact factor: 5.482

Review 8.  Review of Colorectal Studies Using the National Cancer Database.

Authors:  Katherine A Kelley; V Liana Tsikitis
Journal:  Clin Colon Rectal Surg       Date:  2019-01-08

9.  High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer.

Authors:  Rong Liang; Yan Lin; Chun-Ling Yuan; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Jia-Zhou Ye; Hai-Hong Ye
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

10.  MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.

Authors:  Han Zhao; Yu-Zhuo Xie; Rui Xing; Ming Sun; Feng Chi; Yue-Can Zeng
Journal:  Cell Oncol (Dordr)       Date:  2017-05-31       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.